Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:301033's FCF Margin % is ranked better than 93.58% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 0.19
vs SZSE:301033: 24.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medprin Regenerative Medical Technologies Co FCF Margin % Chart
Medprin Regenerative Medical Technologies Co Annual Data
SZSE:301033 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Medprin Regenerative Medical Technologies Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medprin Regenerative Medical Technologies Co FCF Margin % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medprin Regenerative Medical Technologies Co (SZSE:301033) has a FCF Margin % of 28.65% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. According to the industry distribution chart, Medprin Regenerative Medical Technologies Co ranks #53 out of 825 companies in the Medical Devices & Instruments industry, placing it in the top 6.4%.
Is Medprin Regenerative Medical Technologies Co's FCF Margin % too high?
Medprin Regenerative Medical Technologies Co's current FCF Margin % is 28.65%. The Medical Devices & Instruments industry median FCF Margin % is 0.19. Medprin Regenerative Medical Technologies Co's value of 28.65% is 14978.9% above this industry median. Based on the distribution chart, Medprin Regenerative Medical Technologies Co ranks #53 out of 825 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medprin Regenerative Medical Technologies Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medprin Regenerative Medical Technologies Co's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medprin Regenerative Medical Technologies Co ranks #53 out of 825 companies for FCF Margin %. This places Medprin Regenerative Medical Technologies Co in the top 6% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 0.19. Medprin Regenerative Medical Technologies Co's value of 28.65% is 14978.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
The median FCF Margin % among Medical Devices & Instruments companies is 0.19, based on 825 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medprin Regenerative Medical Technologies Co's current FCF Margin % of 28.65% is 14978.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. For the Medical Devices & Instruments industry, the median FCF Margin % is 0.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medprin Regenerative Medical Technologies Co's current FCF Margin % is 28.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medprin Regenerative Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co (SZSE:301033) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥73.38, compared to a current price of ¥53.02 — trading 27.7% below its estimated fair value. The current FCF Margin % is 28.65% and 14978.9% above the Medical Devices & Instruments industry median of 0.19. Medprin Regenerative Medical Technologies Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medprin Regenerative Medical Technologies Co (SZSE:301033), the current FCF Margin % is 28.65% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medprin Regenerative Medical Technologies Co (SZSE:301033) Overvalued in 2026?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co stock appears to be undervalued.
The current stock price of ¥53.02 is trading 27.7% below its estimated GF Value™ of ¥73.38.
GuruFocus considers Medprin Regenerative Medical Technologies Co to be Modestly Undervalued.
Key valuation signals for SZSE:301033:
FCF Margin %: 28.65%
GF Value™: ¥73.38 vs. price of ¥53.02 (27.7% below fair value)
Industry Position: 14978.9% above the Medical Devices & Instruments median (#53 of 825)
No single metric tells the full story. See the SZSE:301033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301033 has been successfully added to your 
